Drug Database
TR

travoprost (Travatan Z / Travantan Z / Travatanz)

✓ Approved

Novartis AG · PTGFR · Small Molecule

What is travoprost?

travoprost is a small molecule developed by Novartis AG. It is approved for therapeutic indications via others.

Drug Profile

Brand NamesTravatan Z, Travantan Z, Travatanz
CompanyNovartis AG
Drug ClassSmall Molecule
Molecular TargetPTGFR
RouteOthers
StatusApproved

Mechanism of Action

Molecular Targets

travoprost acts on 1 molecular target:

PTGFRprostaglandin F receptor (FP)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

travoprost is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Eye disordersGlaucoma✓ Approved

Related Research Articles

PubMedJournal of enzyme inhibition and medicinal chemistry2026-10-15

Rational structure-guided identification of a Bcl-2-targeting peptide with antiproliferative effects on colorectal cancer cells.

Jin Xing X, Yang Shudan S, Wang Qianqian Q, Chen Shutong S et al.

Bcl-2 is critical for tumour survival and serves as a promising anticancer drug target. Herein, a series of novel Bcl-2-targeted peptides were identified through structure-based virtual screening and systematic biological validation. Four candidate peptides were selected from the peptide library. MST results demonstrated that Peptide 1 exhibited the strongest apparent binding affinity towards Bcl-2 (Kd = 0.51 ± 0.03 μM), superior to VS-9 and other screened peptides. Molecular dynamics simulation, free energy landscape analysis, and MM/GBSA calculation further supported the predicted conformational features of the Bcl-2-Peptide-1 complex. MTT assays demonstrated that Peptide-1 markedly inhibited the proliferation of HT29 and Colo320HSR colorectal cancer cells, while showing limited effects on normal NCM460 cells. Bcl-2 knockdown attenuated the bioactivity of Peptide-1, and RT-qPCR and ELISA analyses revealed that Peptide-1 modulated Bax/Bcl-2 expression at both transcriptional and protein levels. Peptide-1 represents a promising Bcl-2-targeting peptide with antiproliferative activity against colorectal cancer cells.

PubMedClinics in orthopedic surgery2026-10-15

Which Injection Is More Effective for Partial-Thickness Rotator Cuff Tear? Atelocollagen Versus Acellular Dermal Matrix.

Lee Kyoung-Geun KG, Cho Sung-Hyun SH, Kim Yang-Soo YS

Collagen-inducing injections are emerging as new treatments for partial-thickness rotator cuff tears (PTRCTs). This study aimed to directly compare the effects of atelocollagen and acellular dermal matrix (ADM) injections on PTRCTs. Between July 2019 and December 2021, 183 patients with PTRCTs who were treated with ultrasound-guided collagen injections were retrospectively enrolled. Two injections were administered at 3-month intervals at the supraspinatus tear site, and tendon integrity was evaluated 6 months after the first injection using magnetic resonance imaging (MRI). The patients were divided into 2 groups: atelocollagen injection (group 1, n = 49) and ADM injection (group 2, n = 41). Supraspinatus tear size was measured in T2 coronal and sagittal views. Outcomes were categorized into 3 groups by tear size change from initial to final follow-up: improved (< 0-2 mm), no interval change (-2 to 2 mm), and worsened (> 2 mm). Clinical scores and range of motion (ROM) were measured in both groups. The atelocollagen group showed improved outcomes in 34.7% of the patients, whereas 55.1% and 10.2% showed no interval change and worsening in the coronal plane, respectively. The ADM group showed improved outcomes in 48.8% of the patients, whereas 48.8% and 2.4% showed no interval change and worsened results in the coronal plane, respectively. The mean change in tear size was -1.02 ± 2.87 mm for group 1 and -2.31 ± 3.62 mm for group 2 (p < 0.05). In the sagittal plane, 20.4% of the patients in group 1 showed improvement, 77.6% showed no interval change, and 2% showed worsened outcomes. Group 2 showed improvement in 31.7% of patients, 58.5% showed no interval change, and 9.8% showed worsened outcomes. Tear size changed by -0.56 ± 1.90 mm for group 1 and -0.8 ± 2.37 mm for group 2 (p > 0.05). No significant differences were noted in the ROM between the 2 groups at any time. Clinical scores also showed no significant differences between the 2 groups, except for the Constant Shoulder Score at the 3-month follow-up. Compared with atelocollagen injection, ADM injection resulted in a superior improvement in rotator cuff tendon integrity. However, clinical outcomes were comparable between the groups.

PubMedInflammopharmacology2026-10-15

A review on MMP-2 modulating agents from natural and synthetic sources and their role in inflammatory bowel disease.

Ragunath Murugasamy M, Ardra Sudarsan S, Balde Akshad A, Nazeer Rasool Abdul RA

Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is characterized by chronic intestinal inflammation, epithelial barrier dysfunction, immune dysregulation, and aberrant extracellular matrix (ECM) remodeling. Matrix metalloproteinase-2 (MMP-2), a zinc-dependent gelatinase, has emerged as a critical regulator of intestinal homeostasis owing to its dual role in tissue repair and inflammatory tissue destruction. Unlike several inducible matrix metalloproteinases, MMP-2 is constitutively expressed and tightly regulated through interactions with membrane-type MMPs, tissue inhibitors of metalloproteinases (TIMPs), cytokines, redox signalling, and microbial factors. Dysregulated MMP-2 activity contributes to epithelial barrier disruption, leukocyte infiltration, chronic inflammation, fibrosis, and disease progression in IBD. This review summarizes the current understanding of MMP-2 biology, activation mechanisms, and immunopharmacological functions in intestinal inflammation, while critically evaluating therapeutic strategies aimed at its modulation. Particular emphasis is placed on natural and synthetic MMP-2 modulators, including animal-derived peptides and endogenous inhibitors, plant-derived polyphenols, flavonoids, alkaloids, terpenoids, and rationally designed small-molecule and peptidomimetic inhibitors. Emerging nanocarrier-based and targeted delivery systems are also discussed as approaches to enhance selectivity and minimize systemic toxicity. Furthermore, the review highlights the limitations of broad-spectrum MMP inhibition and underscores the need for site-specific modulation that preserves physiological tissue remodeling while suppressing pathological activity. Advances in precision medicine, single-cell and spatial transcriptomics, organoid-based disease models, and microbiome-informed therapeutic strategies are expected to facilitate the development of next-generation MMP-2-targeted interventions. Collectively, MMP-2 represents a promising yet complex therapeutic target whose successful modulation may improve long-term outcomes in IBD.

PubMedFrontiers in cardiovascular medicine2026-10-15

Prognostic discrimination of SOFA-2 vs. SOFA-1 and incremental information from cardiovascular scoring and vasoactive support intensity in patients with sepsis receiving early vasoactive therapy.

Huang Tianci T, Pan Mingyuan M, Pan Lifan L, Liang Peng P et al.

Patients with sepsis who require vasoactive support during the first 24 h of intensive care represent a heterogeneous population. It is uncertain whether the Sequential Organ Failure Assessment (SOFA)-2 score improves mortality discrimination compared with the SOFA-1 score and whether observed circulatory support intensity provides complementary prognostic information. This multicohort observational study used Medical Information Mart for Intensive Care IV (MIMIC-IV) for a 24-h conditional landmark analysis. Patients alive and still in the ICU beyond 24 h were followed from ICU admission +24 h through ICU day 28 for reconstructed all-cause mortality. We compared SOFA-1 and SOFA-2, evaluated SOFA-2 total and cardiovascular scores, analyzed first-24-h five-agent norepinephrine-equivalent peak burden (norepinephrine, epinephrine, dopamine, phenylephrine, and vasopressin), and internally evaluated an exploratory drug-composition model. Fixed strata were assessed directionally in eICU Collaborative Research Database and an independent-center high-risk stress test cohort with cohort-specific endpoints. The MIMIC-IV 24-h landmark cohort included 11,892 patients and 2,687 post-landmark deaths. SOFA-2 showed no observed discrimination advantage over SOFA-1 (area under the receiver operating characteristic curve, AUROC, 0.731 vs. 0.732; difference, -0.0005; 95% confidence interval, -0.0086 to 0.0076; P = 0.908). The SOFA-2 cardiovascular score had lower discrimination than the SOFA-1 cardiovascular score (0.663 vs. 0.676; P = 0.006). Mortality was 51.94% for the exploratory SOFA-2 ≥12 group and 17.09% below 12, and increased from 11.30% to 47.45% across four study-defined peak burden categories. The SOFA-2-plus-drug-composition model had an apparent AUROC of 0.768 and a bootstrap-corrected AUROC of 0.767, but it was not externally validated. Fixed strata preserved the direction of risk ranking in both external cohorts, whereas absolute risk and calibration differed. SOFA-2 did not show an observed overall mortality discrimination advantage over SOFA-1 in this population. SOFA-2 total and cardiovascular scores, together with observed vasoactive support intensity, provided complementary prognostic description at 24 h. The ≥12 rule is exploratory, and drug-related associations do not establish causal treatment effects or clinical decision utility.

PubMedFrontiers in nutrition2026-10-15

Impact of a 12-week high-intensity interval training program on working memory in young adults with overweight or obesity.

Zhu Li-Na LN, Yuan Wei W, Gu Qi-Zheng QZ, Yang Qi-Ling QL et al.

To examine the association of a 12-week high-intensity interval training (HIIT) program with working-memory performance in young adults aged 18-25 years with overweight or obesity. A total of 120 young adults with overweight or obesity were randomly allocated to an HIIT group (n = 48) or a control group (n = 72). The HIIT group completed a 12-week structured program, whereas the control group maintained usual daily activities. Working-memory updating was assessed using 1-back and 2-back tasks. Post-test body weight and maximal oxygen consumption (VO2max) were analysed using baseline-adjusted analysis of covariance (ANCOVA), whereas body mass index (BMI) was analysed using repeated-measures ANCOVA. Reaction-time outcomes were analysed using a 2 × 2 × 2 mixed repeated-measures ANCOVA, with group as the between-subject factor and time and cognitive load as within-subject factors. Because marked baseline imbalance was observed for accuracy, 1-back and 2-back accuracy were analysed separately using baseline-adjusted post-test ANCOVA. Exploratory partial correlation analyses examined associations between changes in VO2max and n-back performance separately within the HIIT and control groups. An additional exploratory linear regression model tested whether the association between VO2max improvement and 2-back reaction-time improvement differed between groups. Baseline-adjusted ANCOVA showed lower post-test body weight in the HIIT group than in the control group [F(1,115) = 110.07, p < 0.001, η2 = 0.256] and higher post-test VO2max [F(1,115) = 300.86, p < 0.001, η2 = 0.451]. Repeated-measures ANCOVA showed a significant group × time interaction for BMI [F(1,115) = 137.60, p < 0.001, η2 = 0.545]. For reaction time, the 2 × 2 × 2 mixed repeated-measures ANCOVA showed a significant group × time interaction [F(1,115) = 31.95, p < 0.001, partial η2 = 0.217] and a significant group × cognitive-load interaction [F(1,115) = 9.22, p = 0.003, partial η2 = 0.074], whereas the group × time × cognitive-load interaction was not significant [F(1,115) = 2.15, p = 0.145, partial η2 = 0.018]. After adjustment for baseline accuracy and other measured baseline covariates, no significant post-test group difference was observed in 1-back accuracy [F(1,114) = 0.91, p = 0.343] or 2-back accuracy [F(1,114) = 2.17, p = 0.143]. In exploratory analyses, VO2max improvement was associated with 2-back reaction-time improvement in the HIIT group (r = 0.391, p = 0.009) but not in the control group (r = -0.101, p = 0.411). However, the group × VO2max-improvement interaction did not reach conventional statistical significance (β = 388.57, 95% CI: -7.68 to 784.82, p = 0.055). Participation in the 12-week HIIT program was associated with lower adjusted post-test body weight, higher adjusted post-test VO2max, a greater reduction in BMI, and more favorable reaction-time performance averaged across n-back loads. No adjusted post-test between-group difference in accuracy was observed. The non-significant group × time × cognitive-load interaction does not support a cognitive-load-specific effect. Although the VO2max-2-back reaction-time association was observed in the HIIT group but not in the control group, the non-significant interaction model did not conclusively establish training specificity. Dietary intake, habitual physical activity, sedentary behavior, complete individual-level exercise intensity, and formal assessor blinding were not available; therefore, the observed differences cannot be attributed exclusively to HIIT.

PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-10-15

Product-Reshaped Gas-Phase Hydrodynamics Govern CO2 Electrolysis in Gas Diffusion Electrodes.

Alyahya Abdullah A AA, Tovar-Oliva Mayra S MS, Malimusi Blessings G BG, Murcia-López Sebastián S et al.

High-rate CO 2 electrolysis is commonly assessed using current density, single-pass conversion and Faradaic efficiency, but these global metrics do not indicate whether the local reaction environment required for selective multicarbon formation is preserved during scale-up. Using an experimentally validated, flow-direction-resolved continuum model of a Cu-based gas-diffusion-electrode (GDE) flow-cell system, we demonstrate that gas-fed CO 2 electrolysers behave as reacting-flow electrochemical reactors in which electrochemical conversion transforms the gas phase in the cathode compartment and makes it part of the reactor response. As cathode potential becomes more negative, CO 2 consumption, CO formation and consumption, and gaseous product evolution progressively dilute the CO 2 -rich reacting gas phase, altering gas composition, density and velocity and feeding back into reactant delivery and intermediate availability. This reaction-induced hydrodynamic response creates an operating window favoring ethylene formation and reveals a conservation-driven feedback that becomes unavoidable during scale-up: as electrode length, conversion and gaseous product formation increase, extended electrodes must preserve the spatial overlap between CO 2 delivery, CO generation, controlled CO consumption and limited dilution of the reacting gas phase.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about travoprost